

Perception of patients under biologics or biosimilars



Attitudes
Insights
Satisfaction

carenitix: an innovative platform to analyze
Real-World patient insights in Europe

Expectations
Unmet needs
Awareness

An international and representative panel

900+ patients



5 countries

3 therapeutic areas:

- Rheumatology ~65%
(Rheumatoid Arthritis, Akylosing Spondylitis)
- Gastroenterology ~20%
(Crohn's disease, Ulcerative colitis)
- Dermatology ~15%
(Psoriasis, Psoriatic Arthritis)

Methodology & Objectives

DELIVERABLE

150+ pages of in-depth analysis and recommendations

METHODOLOGY

Ad hoc online research: all of Carenity's community with conditions in-scope were invited to participate via email

Frequency: 2 waves per year

OBJECTIVES

- Assess patients' awareness and perception of biologics/biosimilars
- Understand patients' expectations on support and information
- Evaluate patients' perception of current biologics
- Assess biologics and manufacturers awareness

Treatments studied



Patients' awareness and perception of biologics/biosimilars

- Understanding of what a biosimilar is
- Willingness to switch, rationale and general attitude vis-à-vis biosimilars



Patients' perception of current biologics

- Influence and criteria of choice for a new treatment / switch rationale
- Level of satisfaction vis-à-vis biologics
- Impact of Tx on Quality of Life per treatment
- General benefits and drawbacks of biologics

Biologics and manufacturers awareness

- Unaided awareness
- Aided awareness

Patients' expectations on support and information

- Services and tools for disease monitoring
- Missing disease-related information
- Main expectations on disease management

Extracts from 2016 study

Heatmap: Orenzia has a very positive evolution in the perception of patients.

3/4 patients currently under biologics do not know what a biosimilar is.


Nearly 1/2 patients under biologics believe that using a biosimilar is riskier than biologics.

	Humira	Enbrel	Remicade	Simponi	Cimzia	RoActemra	Orenzia	Stelara	MabThera
Flare-ups decrease	-0,2	-0,1	+0,2	+0,1	-0,1	-0,4	+0,7	-1,2	-2,0
Handicap decrease	-0,2	-0,1	+0,1	=	+0,1	-0,4	+0,6	-1,7	-1,8
Fatigue decrease	-0,1	-0,1	=	=	+0,1	-0,2	-1,2	-0,2	-2,3
Pain decrease	-0,5	-0,3	+0,2	-0,2	-0,4	-0,2	+0,1	-0,7	-1,3
Enhancing QoL	-0,2	-0,3	=	=	-0,2	-0,7	-0,1	-1,0	-1,3
Taking treatment with ease	-0,2	-0,5	-0,5	-0,2	-0,1	-0,1	-0,4	-1,1	-0,7
Treatment intake frequency	-0,4	-0,6	-0,9	-0,6	=	-0,3	+0,8	-1,3	-0,8
Tolerance to treatment	-0,4	-0,2	-0,1	-0,5	+0,5	+0,4	+0,7	-1,3	-2,6
Risks related to treatment intake	-0,5	+0,5	-0,8	-0,6	+0,4	-1,1	+0,3	-1,7	-2,8
Overall satisfaction	-0,3	-0,1	+0,1	-0,1	-0,1	-0,5	+0,4	-1,6	-2,6

Evolution : -10 (red) to 10 (green) | Biotherapy (blue)


Decision: 7 patients out of 10 have played a role in choosing their treatment.

Q: In addition to your specialist practitioner, who was involved or influenced your treatment's choice?



Patient satisfaction: 1 treatment is less suited than the other 2.

Q: What is your level of satisfaction regarding your treatment?



And many more...